Tysabri has shown it: (1) stabilizes EDSS over time, (2) improves ambulatory function in disabled RRMS patients, (3) increases walking speed, (4) improves fatigue, (5) improves attention and depression, (6) improves cognition, (7) improves bladder function, (8) reduces axonal damage; (9) it reduced annual relapse rate by over 90% in 563 Belgian patients, (10) reduces MRI lesions, and (11) Tysabri has demonstrated higher effectiveness in clinical, real world use than in pivotal trials.
1. 1,024 patients studied showed, “stability of EDSS scores and consistently low relapse rates over 5 years of natalizumab treatment…” http://www.ncbi.nlm.nih.gov/pubmed/24898925
2. Natalizumab improves ambulatory function in disabled RRMS subjects http://www.ncbi.nlm.nih.gov/pubmed/23308186
3. “Natalizumab increased walking speed in patients with relapsing-remitting multiple sclerosis” http://www.ncbi.nlm.nih.gov/pubmed/25511792
4. Significant improvements in fatigue maintained over time http://www.ncbi.nlm.nih.gov/pubmed/24453774
5. “Results show a positive effect of Natalizumab on attention in patients with RRMS, and for the first time, also in depression after 2 years of observation” http://www.ncbi.nlm.nih.gov/pubmed/26029156
6. Natalizumab Significantly Improves Cognitive Impairment Over 3 Years http://www.ncbi.nlm.nih.gov/pubmed/26148120
7. “Patients treated with natalizumab experience significantly improved incontinence-related QOL” “http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967702/
8. Reduced axonal damage under natalizumab treatment http://www.ncbi.nlm.nih.gov/pubmed/23763388
9. “… 563 patients included in Tysabri observational program (TOP) between December 2007 and 2012 from Belgium… The annualized relapse rate on treatment was reduced by 90.7%” http://www.ncbi.nlm.nih.gov/pubmed/24915752
10. Sustained Disability Improvement Associated With Reduced MRI Lesion Burden In Natalizumab-Treated Patients With MS http://www.neurology.org/content/82/...plement/P4.192
11. Tysabri’s “effectiveness in clinical practice is higher than that reported in pivotal trials and was maintained over time. http://www.ncbi.nlm.nih.gov/pubmed/25004826
Tysabri carries risk of a deadly brain disease called PML. There have been about 570 cases of PML in about 140,000 MSers who have taken Tysabri. Methods to mitigate PML risk are being discovered.
The JC virus causes PML. There is a JC virus antibody test. Those who do not have JC virus typically cannot get PML unless they convert and become positive. There is a large ongoing study of extending time between infusions as a method to reduce PML risk. So far, no one doing dose extension has gotten PML.
1. 1,024 patients studied showed, “stability of EDSS scores and consistently low relapse rates over 5 years of natalizumab treatment…” http://www.ncbi.nlm.nih.gov/pubmed/24898925
2. Natalizumab improves ambulatory function in disabled RRMS subjects http://www.ncbi.nlm.nih.gov/pubmed/23308186
3. “Natalizumab increased walking speed in patients with relapsing-remitting multiple sclerosis” http://www.ncbi.nlm.nih.gov/pubmed/25511792
4. Significant improvements in fatigue maintained over time http://www.ncbi.nlm.nih.gov/pubmed/24453774
5. “Results show a positive effect of Natalizumab on attention in patients with RRMS, and for the first time, also in depression after 2 years of observation” http://www.ncbi.nlm.nih.gov/pubmed/26029156
6. Natalizumab Significantly Improves Cognitive Impairment Over 3 Years http://www.ncbi.nlm.nih.gov/pubmed/26148120
7. “Patients treated with natalizumab experience significantly improved incontinence-related QOL” “http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967702/
8. Reduced axonal damage under natalizumab treatment http://www.ncbi.nlm.nih.gov/pubmed/23763388
9. “… 563 patients included in Tysabri observational program (TOP) between December 2007 and 2012 from Belgium… The annualized relapse rate on treatment was reduced by 90.7%” http://www.ncbi.nlm.nih.gov/pubmed/24915752
10. Sustained Disability Improvement Associated With Reduced MRI Lesion Burden In Natalizumab-Treated Patients With MS http://www.neurology.org/content/82/...plement/P4.192
11. Tysabri’s “effectiveness in clinical practice is higher than that reported in pivotal trials and was maintained over time. http://www.ncbi.nlm.nih.gov/pubmed/25004826
Tysabri carries risk of a deadly brain disease called PML. There have been about 570 cases of PML in about 140,000 MSers who have taken Tysabri. Methods to mitigate PML risk are being discovered.
The JC virus causes PML. There is a JC virus antibody test. Those who do not have JC virus typically cannot get PML unless they convert and become positive. There is a large ongoing study of extending time between infusions as a method to reduce PML risk. So far, no one doing dose extension has gotten PML.
Comment